Mary Butler
Overview
Explore the profile of Mary Butler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
111
Citations
1638
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Desai P, Urosevic S, Butler M
Bipolar Disord
. 2021 Jul;
23(4):321-323.
PMID: 34312953
No abstract available.
22.
Wagner-Skacel J, Dalkner N, Bengesser S, Ratzenhofer M, Fink N, Kahn J, et al.
Front Psychiatry
. 2021 Jul;
12:671383.
PMID: 34295270
The coronavirus disease 2019 (COVID-19) pandemic has resulted in widespread socioeconomic restrictions including quarantine, social distancing and self-isolation. This is the first study investigating the psychological impact of the pandemic...
23.
McAndrew N, Mark L, Butler M
Crit Care Nurse
. 2020 Dec;
40(6):42-51.
PMID: 33257964
Background: Organizations motivated to provide high-quality care in the intensive care unit are exploring strategies to engage families in patient care. Such initiatives are based on emerging evidence that family...
24.
Hemmy L, Linskens E, Silverman P, Miller M, Talley K, Taylor B, et al.
Ann Intern Med
. 2020 Apr;
172(10):678-687.
PMID: 32340040
Background: The accuracy and harms of brief cognitive tests for identifying clinical Alzheimer-type dementia (CATD) are uncertain. Purpose: To summarize evidence on accuracy and harms of brief cognitive tests for...
25.
Fink H, Linskens E, Silverman P, McCarten J, Hemmy L, Ouellette J, et al.
Ann Intern Med
. 2020 Apr;
172(10):669-677.
PMID: 32340038
Background: Biomarker accuracy for Alzheimer disease (AD) is uncertain. Purpose: To summarize evidence on biomarker accuracy for classifying AD in older adults with dementia. Data Sources: Electronic bibliographic databases (searched...
26.
Fink H, Linskens E, MacDonald R, Silverman P, McCarten J, Talley K, et al.
Ann Intern Med
. 2020 Apr;
172(10):656-668.
PMID: 32340037
Background: Effects of drug treatment of clinical Alzheimer-type dementia (CATD) are uncertain. Purpose: To summarize evidence on the effects of prescription drugs and supplements for CATD treatment. Data Sources: Electronic...
27.
Schwehr N, M Kuntz K, Enns E, Shippee N, Kingwell E, Tremlett H, et al.
Drugs Aging
. 2020 Jan;
37(3):225-235.
PMID: 31916231
Background: For older adults with relapsing-onset multiple sclerosis (MS), limited information is available to inform if, or when, disease-modifying drugs (DMDs) may be safely discontinued. Objective: The aim of this...
28.
Hale L, Mayland E, Jenkins M, Buttery Y, Norris P, Butler M, et al.
Gerontologist
. 2019 Nov;
60(5):905-915.
PMID: 31722390
Background And Objectives: People with dementia are critically dependent on their carers when accessing and utilizing health care. To inform health care development and delivery, we aimed to explore carers'...
29.
Adam G, Balk E, Jap J, Senturk B, Sanders-Schmidler G, Lallinger K, et al.
Jt Comm J Qual Patient Saf
. 2019 Sep;
45(9):629-638.
PMID: 31488251
Methods: An open-source Web-based interactive report presentation of a systematic review was developed to allow users to generate their own "reports" from the information produced by the review. Data from...
30.
Schwehr N, M Kuntz K, Butler M, Enns E, Shippee N, Kingwell E, et al.
Mult Scler
. 2019 Jul;
26(12):1510-1518.
PMID: 31354041
Background: Relapsing-onset multiple sclerosis (MS) typically starts in early- to mid-adulthood, yet the trajectory of disease activity over the subsequent lifetime remains poorly defined. Previous studies have not quantified the...